PMC:4038391 / 8400-9727 JSONTXT

{"project":"2_test","denotations":[{"id":"24637492-9635921-79073625","span":{"begin":179,"end":180},"obj":"9635921"},{"id":"24637492-14617629-79073626","span":{"begin":182,"end":184},"obj":"14617629"},{"id":"24637492-18452169-79073627","span":{"begin":273,"end":275},"obj":"18452169"},{"id":"24637492-21559403-79073628","span":{"begin":451,"end":453},"obj":"21559403"}],"text":"Extracellular S100P increases survival of BxPC3 exposed to Gemcitabine and anti-S100P mAbs block this activity\nS100P expression was correlated with chemoresistance by some studies6, 12 being proposed as a marker to predict the effectiveness of some chemotherapeutics drugs.21 Other authors demonstrated that extracellular S100A14 increased the survival of the KYSE180 esophageal squamous carcinoma cell line exposed to the cytotoxic agent Doxorubicin.22 To gain insights into a possible similar effect of S100P in pancreatic carcinoma cells, we exposed BxPC3 cells to Gemcitabine alone and in combination with increased concentrations of S100P. First, we determined the EC50 of Gemcitabine (Figure 3a). Next, we combined this concentration (23 nM) with different doses of recombinant human S100P (0–750 nM). The addition of S100P protected cells from damage induced by Gemcitabine in a concentration-dependent manner with a statistically significant effect for S100P concentrations from 180 nM onwards (Figure 3b). To further confirm the protective effect of S100P and the efficacy of our neutralizing mAbs, a 10-fold increase of Gemcitabine (200 nM) was combined with 500 nM of S100P. As shown, antibodies significantly abrogated the effect of S100P and sensitized the cells to the cytotoxic effect of Gemcitabine (Figure 3c)."}